Skip to main content

Table 1 Clinicopathological features of the general cohort population

From: Digital imaging-assisted quantification of H3K27me3 immunoexpression in luminal A/B-like, HER2-negative, invasive breast cancer predicts patient survival and risk of recurrence

VariablesN%
Luminal subtypes
 A-like6641.3
 B-like9458.8
 IDC (versus others)13383.1
Grade
 G122/15813.9
 G281/15851.3
 G355/15834.8
pT Stage
 pT155/14837.2
 pT287/14858.8
 pT3-p/cT4a6/1484.0
pN Stage
 pN-68/15344.4
 pN+85/15355.6
 pN+≥ 4 nodes35/8541.2
Adjuvant Treatment
 Adjuvant CT63/10063.0
 Adjuvant RT117/14381.8
 Adjuvant ET128/13297.0
 Adjuvant TMX only93/12872.7
 Adjuvant TMX + AI34/12826.6
 Adjuvant TMX + GOS1/1280.8
Recurrence4226.3
 Early recurrence22/4252.4
 ET-resistant recurrence24/4257.1
 Systemic recurrence33/4278.6
Death3521.9
  1. n = 160 unless otherwise specified. aT3 and T4 cases analyzed conjointly due to low N (see text for further details) Abbreviations: AI Aromatase inhibitor, CT Chemotherapy, ET Endocrine treatment, GOS Goserelin, IDC Invasive ductal carcinoma, RT Radiotherapy, TMX Tamoxifen